Citations

Showing 10 of 108152 citations.

Ten-year all-cause death after percutaneous or surgical revascularization in diabetic patients with complex coronary artery disease
Wang, Rutao , Serruys, Patrick W. , Gao, Chao , Hara, Hironori , Takahashi, Kuniaki , Ono, Masafumi , Kawashima, Hideyuki , O’Leary, Neil , Holmes, David R. , Curzen, Nick , Geuns, Robert‐Jan van , Morel, Marie‐Angèle , Head, Stuart J., Thuijs, Daniel J.F.M. , Davierwala, Piroze , O’Brien, Timothy , Garg, Scot , Onuma, Yoshinobu , Witkowski, Adam , Curzen, Nick , Burzotta, Francesco , Kappetein, Arie Pieter , Thuijs, Daniel J F M , Garg, Scot , Serruys, Patrick W , Onuma, Yoshinobu , Witkowski, Adam , James, Stefan Karl , Kappetein, A. Pieter , Fuster, Valentı́n

Mayo Clinic

European Heart Journal | August 13, 2021 | Volume: 43 | Issue: 1 | Pages: 56-67

10.1093/eurheartj/ehab441 | PMID 34405232 Get It

Abstract Aims The aim of this article was to compare rates of all-cause death at 10 years following coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) in patients with or without diabetes. Methods and results The SYNTAXES study evaluated up to 10-year survival of 1800 patients with three-vessel disease (3VD) and/or left main coronary artery disease (LMCAD) randomized to receive either PCI or CABG in the SYNTAX trial. Ten-year all-cause death according to diabetic status and revascularization strategy was examined. In diabetics (n = 452), the risk of mortality was numerically higher with PCI compared with CABG at 5 years [19.6% vs. 13.3%, hazard ratio (HR): 1.53, 95% confidence interval (CI): 0.96, 2.43, P = 0.075], with the opposite seen between 5 and 10 years (PCI vs. CABG: 20.8% vs. 24.4%, HR: 0.82, 95% CI: 0.52, 1.27, P = 0.366). Irrespective of diabetic status, there was no significant difference in all-cause death at 10 years between patients receiving PCI or CABG, the absolute treatment difference was 1.9% in diabetics (PCI vs. CABG: 36.4% vs. 34.5%, difference: 1.9%, 95% CI: −7.6%, 11.1%, P = 0.551). Among insulin-treated patients (n = 182), all-cause death at 10 years was numerically higher with PCI (47.9% vs. 39.6%, difference: 8.2%, 95% CI: −6.5%, 22.5%, P = 0.227). Conclusions The treatment effects of PCI vs. CABG on all-cause death at 10 years in patients with 3VD and/or LMCAD were similar irrespective of the presence of diabetes. There may, however, be a survival benefit with CABG in patients with insulin-treated diabetes. The association between revascularization strategy and very long-term ischaemic and safety outcomes for patients with diabetes needs further investigation in dedicated trials. Trial registration SYNTAX: ClinicalTrials.gov reference: NCT00114972 and SYNTAX Extended Survival: ClinicalTrials.gov reference: NCT03417050.
Interferon drives HCV scarring of the epigenome and creates targetable vulnerabilities following viral clearance
Hlady, Ryan A. , Zhao, Xia , Khoury, Louis Y. El , Luna, Aesis , Pham, Kien , Wu, Qunfeng , Lee, Jeong‐Heon , Pyrsopoulos, Nikolaos , Liu, Chen , Robertson, Keith D. , El Khoury, Louis Y, Robertson, Keith D , Lee, Jeong-Heon , El Khoury, Louis Y , Liu, Chen

Mayo Clinic

Hepatology | August 13, 2021 | Volume: 75 | Issue: 4 | Pages: 983-996

10.1002/hep.32111 | PMID 34387871 Get It

Abstract Background and Aims Chronic HCV infection is a leading etiologic driver of cirrhosis and ultimately HCC. Of the approximately 71 million individuals chronically infected with HCV, 10%‐20% are expected to develop severe liver complications in their lifetime. Epigenetic mechanisms including DNA methylation and histone modifications become profoundly disrupted in disease processes including liver disease. Approach and Results To understand how HCV infection influences the epigenome and whether these events remain as “scars” following cure of chronic HCV infection, we mapped genome‐wide DNA methylation, four key regulatory histone modifications (H3K4me3, H3K4me1, H3K27ac, and H3K27me3), and open chromatin in parental and HCV‐infected immortalized hepatocytes and the Huh7.5 HCC cell line, along with DNA methylation and gene‐expression analyses following elimination of HCV in these models through treatment with interferon‐α (IFN‐α) or a direct‐acting antiviral (DAA). Our data demonstrate that HCV infection profoundly affects the epigenome (particularly enhancers); HCV shares epigenetic targets with interferon‐α targets; and an overwhelming majority of epigenetic changes induced by HCV remain as “scars” on the epigenome following viral cure. Similar findings are observed in primary human patient samples cured of chronic HCV infection. Supplementation of IFN‐α/DAA antiviral regimens with DNA methyltransferase inhibitor 5‐aza‐2’‐deoxycytidine synergizes in reverting aberrant DNA methylation induced by HCV. Finally, both HCV‐infected and cured cells displayed a blunted immune response, demonstrating a functional effect of epigenetic scarring. Conclusions Integration of epigenetic and transcriptional data elucidate key gene deregulation events driven by HCV infection and how this may underpin the long‐term elevated risk for HCC in patients cured of HCV due to epigenome scarring.
Early detection of pancreatic cancer: current state and future opportunities
Trikudanathan, Guru , Majumder, Shounak , Majumder, Shounak , Lou, Emil , Maitra, Anirban

Mayo Clinic

Current Opinion in Gastroenterology | August 13, 2021 | Volume: 37 | Issue: 5 | Pages: 532-538

10.1097/mog.0000000000000770 | PMID 34387255 Get It

Purpose of review Pancreatic ductal adenocarcinoma (PDAC) is third leading cause of cancer death in the United States, a lethal disease with no screening strategy. Although diagnosis at an early stage is associated with improved survival, clinical detection of PDAC is typically at an advanced symptomatic stage when best in class therapies have limited impact on survival. Recent findings In recent years this status quo has been challenged by the identification of novel risk factors, molecular markers of early-stage disease and innovations in pancreatic imaging. There is now expert consensus that screening may be pursued in a cohort of individuals with increased likelihood of developing PDAC based on genetic and familial risk. Summary The current review summarizes the known risk factors of PDAC, current knowledge and recent observations pertinent to early detection of PDAC in these risk groups and outlines future approaches that will potentially advance the field.
Current Trends and Controversies in the Management of Warthin Tumor of the Parotid Gland
Quer, Miquel , Hernandez‐Prera, Juan C. , Silver, Carl E., Casasayas, María , Simó, Ricard , Poorten, Vincent Vander , Guntinas‐Lichius, Orlando , Bradley, Patrick J. , Ng, Wai Tong , Rodrigo, Juan P. , Mäkitie, Antti , Rinaldo, Alessandra , Kowalski, Luiz Paulo , Sanabria, Álvaro , Bree, Remco de , Takes, Robert P. , López, Fernando , Olsen, Kerry D., Shaha, Ashok R. , Ferlito, Alfio , Tong-Ng, Wai , Mäkitie, Antti A , de Bree, Remco , Rodrigo, Juan P , Kowalski, Luiz P , Vander Poorten, Vincent , Sanabria, Alvaro

Mayo Clinic

Diagnostics | August 13, 2021 | Volume: 11 | Issue: 8 | Pages: 1467

10.3390/diagnostics11081467 | PMID 34441400 Get It

Purpose: To review the current options in the management of Warthin tumors (WTs) and to propose a working management protocol. Methods: A systematic literature search was conducted using PubMed and ScienceDirect database. A total of 141 publications were selected and have been included in this review. Publications were selected based on relevance, scientific evidence, and actuality. Results: The importance of parotid WTs is increasing due to its rising incidence in many countries, becoming the most frequently encountered benign parotid tumor in certain parts of the world. In the past, all WTs were treated with surgery, but because of their slow growth rate, often minimal clinical symptoms, and the advanced age of many patients, active observation has gradually become more widely used. In order to decide on active surveillance, the diagnosis of WT must be reliable, and clinical, imaging, and cytological data should be concordant. There are four clear indications for upfront surgery: uncertain diagnosis; cosmetic problems; clinical complaints, such as pain, ulceration, or recurrent infection; and the patient’s wish to have the tumor removed. In the remaining cases, surgery can be elective. Active surveillance is often suggested as the first approach, with surgery being considered if the tumor progresses and/or causes clinical complaints. The extent of surgery is another controversial topic, and the current trend is to minimize the resection using partial parotidectomies and extracapsular dissections when possible. Recently, non-surgical options such as microwave ablation, radiofrequency ablation, and ultrasound-guided ethanol sclerotherapy have been proposed for selected cases. Conclusions: The management of WT is gradually shifting from superficial or total parotidectomy to more conservative approaches, with more limited resections, and to active surveillance in an increasing number of patients. Additionally, non-surgical treatments are emerging, but their role needs to be defined in future studies.
atg7 -Based Autophagy Activation Reverses Doxorubicin-Induced Cardiotoxicity
Wang, Yong , Lu, Xiaoguang , Wang, Xiaoping , Qiu, Qi , Zhu, Ping , Ma, Lin , Ma, Xiao , Herrmann, Joerg , Wang, Wei , Lin, Xueying , Ma, Xiao , Xu, Xiaolei

Mayo Clinic

Circulation Research | August 13, 2021 | Volume: 129 | Issue: 8 | Pages: No page available

10.1161/circresaha.121.319104 | PMID 34384247 Get It

Rationale: Anthracycline-induced cardiotoxicity (AIC) is a major side effect that limits the use of anthracyclines as effective chemotherapeutics. No mechanism-based therapy is available when cardiac function deteriorates. Objective: We aim to elucidate the dynamic autophagic defects in AIC and to identify a mechanism-based therapy via both genetic and pharmacological studies. Method and Results: Through phenotyping an adult AIC zebrafish model, we detected a biphasic response in autophagy: activation in the early stage and suppression in the later phase that is characterized by a decline in cardiac function. We conducted conditional genetic studies with atg7 , which encodes a rate-limiting autophagy core protein, and found that atg7 overexpression leads to therapeutic effects in the late phase but deleterious effects in the early phase of adult AIC. We then assessed the therapeutic effects of 37 Food and Drug Administration–approved autophagy activators using an embryonic AIC zebrafish model and identified spironolactone, pravastatin, and minoxidil as top-ranking drugs. We demonstrated the therapeutic efficacy of these Food and Drug Administration–approved autophagy activators in the adult AIC model and confirmed that these drugs exert therapeutic effects in the late phase but not in the early AIC phase. Finally, we demonstrated that the time-dependent therapeutic effects are conserved in a mouse AIC model and that spironolactone and rapamycin activated autophagy in an Atg7-dependent fashion. Conclusions: Our findings suggest that atg7-based autophagy activation is an effective therapeutic avenue to reversing the decline in cardiac function in AIC, highlighting the time-dependent nature of autophagy-based therapy.
Susceptibility Locus for Pregnancy-Associated Spontaneous Coronary Artery Dissection
Turley, Tamiel N. , Kosel, Matthew , Gulati, Rajiv , Hayes, Sharonne N. , Tweet, Marysia S. , Olson, Timothy M. , Hayes, Sharonne N , Tweet, Marysia S , Bamlet, William R.

Mayo Clinic

Circulation: Genomic and Precision Medicine | August 13, 2021 | Volume: 14 | Issue: 4 | Pages: No page available

10.1161/circgen.121.003398 | PMID 34384238 Get It

EEG Biomarkers of Repository Corticotropin Injection Treatment
Tanritanir, Ahmet, Vieluf, Solveig , Wang, Xiao‐Fan , Jafarpour, Saba, Jafarpour, Saba , Loddenkemper, Tobias , Vieluf, Solveig

Mayo Clinic

Journal of Clinical Neurophysiology | August 13, 2021 | Volume: 40 | Issue: 3 | Pages: 236-243

10.1097/wnp.0000000000000886 | PMID 34387275 Get It

Purpose: Hypsarrhythmia is one of the major diagnostic and treatment response criteria in infantile spasms (IS). The clinical and electrophysiological effect of repository corticotropin injection treatment on IS was evaluated using electrophysiological biomarkers. Methods: Consecutive infants (<24 months) treated with repository corticotropin injection for IS were included in this retrospective descriptive study. Inclusion criteria were (1) clinical IS diagnosis, (2) repository corticotropin injection treatment, and (3) consecutive EEG recordings before and after repository corticotropin injection treatment. Patients with tuberous sclerosis complex were excluded. Response to treatment was defined as freedom from IS for at least 7 consecutive days during the treatment and resolution of hypsarrhythmia. The authors defined “relapse” as the recurrence of seizures after an initial response. Electrophysiological biomarker assessment included evaluation of semiautomatic spike counting algorithm, delta power, and delta coherence calculation during non-REM sleep EEG. Results: One hundred fifty patients (83 males; 55%; median age of IS onset: 5.9 months) with complete data were included, including 101 responders (67%, 71 with sustained response, and 30 relapses). Fifty patients (33%) with complete EEG data also underwent advanced EEG analysis. Baseline delta coherence was higher in sustained responders than in nonresponders or patients who relapsed. Greater decreases in semiautomatic spike counting algorithm, delta power, and delta coherence were found in sustained responders compared with nonresponders or patients who relapsed. Conclusions: Repository corticotropin injection treatment was associated with a 67% response rate in patients with IS. Computational biomarkers beyond hypsarrhythmia may provide additional information during IS treatment, such as early determination of treatment response and outcome assessment.
Imaging cytoplasmic lipid droplets in vivo with fluorescent perilipin 2 and perilipin 3 knock-in zebrafish
Wilson, Meredith H. , Ekker, Stephen C. , Farber, Steven , Farber, Steven Arthur , Ekker, Stephen C

Mayo Clinic

eLife | August 13, 2021 | Volume: 10 | Issue: No issue available | Pages: No page available

10.7554/elife.66393 | PMID 34387191 Get It

Cytoplasmic lipid droplets are highly dynamic storage organelles that are critical for cellular lipid homeostasis. While the molecular details of lipid droplet dynamics are a very active area of investigation, this work has been primarily performed in cultured cells. Taking advantage of the powerful transgenic and in vivo imaging opportunities available in zebrafish, we built a suite of tools to study lipid droplets in real time from the subcellular to the whole organism level. Fluorescently tagging the lipid droplet-associated proteins, perilipin 2 and perilipin 3, in the endogenous loci permits visualization of lipid droplets in the intestine, liver, and adipose tissue. Using these tools, we found that perilipin 3 is rapidly loaded on intestinal lipid droplets following a high-fat meal and later replaced by perilipin 2. These powerful new tools will facilitate studies on the role of lipid droplets in different tissues, under different genetic and physiological manipulations, and in a variety of human disease models.
Dramatic Presentation of Cardiac Pleomorphic Liposarcoma
Tan, Nicholas Y. , Najam, Maria , Lyle, Melissa , Maleszewski, Joseph J. , Collins, Jeremy D. , Klarich, Kyle W. , Lyle, Melissa A. , Collins, Jeremy

Mayo Clinic

Circulation: Cardiovascular Imaging | August 13, 2021 | Volume: 14 | Issue: 8 | Pages: No page available

10.1161/circimaging.121.012620 | PMID 34387092 Get It

Glioma: interaction of acquired and germline genetics
Eckel‐Passow, Jeanette E. , Jenkins, Robert B. , Lachance, Daniel Honore

Mayo Clinic

Aging | August 13, 2021 | Volume: 13 | Issue: 15 | Pages: 19085-19087

10.18632/aging.203428 | PMID 34385404 Get It